ZA200103768B - 2,4-Disubstituted triazine derivatives. - Google Patents

Description

" i { /

N

2.4-DISUBSTITUTED TRIAZINE DERIVATIVES

EE

The present invention is concerned with 2 4-disubstituted triazine derivatives having

HIV replication inhibiting properties. The invention further relates to methods for their preparation and pharmaceutical compositions comprising them. The invention also relates to the use of said compounds in the manufacture of a medicament useful for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. EP-0,834,507 discloses substituted diamino 1,3,5-triazine derivatives having HIV replication inhibiting properties. The present compounds differ from the known 1,3,5- triazines by structure and by their improved HIV replication inhibiting properties.

The present invention concerns the use of the compounds of formula rR!

LN k — ®?),

YEE

No zN l=,2 the N-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms thereof, wherein ’ -a'=a’-a’=a’- represents a bivalent radical of formula -CH=CH-CH=CH- (a-1); -N=CH-CH=CH- (a-2); -N=CH-N=CH- (a-3); : -N=CH-CH=N- (a-4); : -N=N-CH=CH- (a-5); nis 0, 1,2, 3 or 4; and in case -a'=a’-a’=a*- is (a-1), then n may also be 5; : 25 R'is hydrogen, aryl, formyl, C,.salkylcarbonyl, C, alkyl, C,.salkyloxycarbonyl, C,.calkyl substituted with formyl, C, salkylcarbonyl, C,alkyloxycarbonyl; and each R? independently is hydroxy, halo, Cj.galkyl optionally substituted with cyano or > -C(=O)R®, Cs.scycloalkyl, C;.galkenyl optionally substituted with one or more halogen atoms or cyano, Ca.alkynyl optionally substituted with one or more halogen atoms or cyano, C,salkyloxy, C, calkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C).salkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=0),R%, -NH-S(=0),R", -C(=0)R%, -NHC(=0)H, -C(=O)NHNH,, -NHC(=O)R*,-C(=NH)R" or a radical of formula oo he) (©) =A wherein each A independently is N, CH or CR

Bis NH, O, S or NR; pis ior2; and

R* is methyl, aming, monce- or dimethylamino or pelyhaiomethy!:

Tis jgaikyl, Cs alkenyl, Coanalkynyl, Cascycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from * (Cjscycloalkyl, * indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, C;¢atkyl, hydroxy,

C..calkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C,alkylcarbonyl, + phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R% or

Lis -X-R’ wherein

R? is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in RZ? and

X is -NR'-, -NH-NH-, -N=N-, -O-, -C(=0)-, -CHOH-, -S-, -8(=0)- or -S(=0)z-; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C,alkyl, Cascycloalkyl, C,.salkyloxy, cyano, nitro, polyhaleC.galky! and polyhaloC, salkyloxy; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

This invention also concerns compounds of formula (I') which are defined as compounds of formula (I) wherein the compounds cited in the following references * Recl. Trav. Chim. Pays-Bas (1569), 88(4), 426-38. x Polym. I. (Tokyo) (1996), 28(4), 337-42. > % J. Inst. Chem. (India) {1978}, 50(5), 213-14. * Nippon Kagaku Kaishi (1977), Issue 4, 549-55. : * Kobunshi Kagaku (1973), 30(12), 720-6. * SU 189438 = DE 2226474 are excluded; i.e. compounds of formula oo - & h J -3-

R!

LN k — (RY),

CEE

. NN a'=a? the N-oxides, addition salts, quaternary amines and stereochemically isomeric forms thereof, wherein the substituents are as defined under formula (I); with the proviso that .

S compounds wherein_ * Lis Cyalkyl; R'is selected from hydrogen, ethyl and methyl; -a'=a’-a’=a"- represents a bivalent radical of formula (a-1);nisOorl and R? is selected from fluoro, chloro, methyl, trifluoromethyl, ethyloxy and nitro; or + Lis -X-R3, X is -NH-; R' is hydrogen; -a'=a’-a’=a’- represents a bivalent radical of formula (a-1); nis 0 orl and R? is selected from chloro, methyl, methyloxy, cyano, amino and nitro and R? is phenyl, optionally substituted with one substituent selected from chloro, methyl, methyloxy, cyano, amino and nitro; and the compounds * N,N’-dipyridinyl-(1,3,5)-triazine-2,4-diamine; = (4-chloro-phenyl)-(4(1-(4-isobutyl-phenyl)-ethyl)-(1,3,5) triazin-2-yl)-amine are not included. : : A special group of compounds are compounds of formula (I'), the N-oxides, addition : salts, quaternary amines and stereochemically isomeric forms thereof, wherein -a'=a’-a’=a’- represents a bivalent radical of formula - -CH=CH-CH=CH- (a-1); -N=CH-CH=CH- (a-2); -N=CH-N=CH- (a-3); -N=CH-CH=N- (a-4); -N=N-CH=CH- (a-5); nis 0, 1,2, 3 or 4; and in case -a'=a’-a’=a*- is (a-1), then n may also be 5;

R'is hydrogen, aryl, formyl, C,alkylcarbonyl, C 1salkyl, C, salkyloxycarbonyl, C, alkyl . substituted with formyl, C, salkylcarbonyl, C,alkyloxycarbonyl; and

Co each R? independently is hydroxy, halo, Cj-galkyl optionally substituted with cyano or oo 30 -C(=0)R?, Cs.1cycloalkyl, Cz.alkenyl optionally substituted with one or more halogen atoms or cyano, C;.¢alkynyl optionally substituted with one or more halogen atoms or cyano, C,alkyloxy, C .salkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C).¢alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=0),R*, -NH-S(=0),R", -C(=0)R*, -NHC(=O)H, _C(=0)NHNH,, -NHC(=0)R*,-C(=NH)R* or a radical of formula

PA ©

Bl wherein each A independently is N, CH or CR

Bis NH, O, S or NR%; pis 1 or2; and -

R% ic methyl, amino, monn- or dimethylamino or polyhalomethyl:

L is Ca.10alkyl, Ca.10atkenyl, Ca.i0alkynyl, Csscycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from * Cyycycloalkyl, # indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, C,.salkyl, hydroxy, C,salkyl- oxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and

C.salkylcarbonyl, * phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridaziny, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five i5 substituents each independently selected from the substituents defined in rR” or

Lis -X-R> wherein

R? is phenyl, pyridinyl, pyrimidinyi, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with two, three, four or five substituents each independently selected from the substituents defined in R% and :

X is -NR'-, -NH-NH-, -N=N-, -O-, -C(=0)-, -CHOH-, -8-, -$(=0)- or -5(=0)2-; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from hale, C.salkyl, Cs.cycloalkyl, C,salkyloxy, cyanc, nitro, polyhaloC,.¢alkyl and polyhaloC, ealkyloxy; ’s and suitably N,N’-dipyridinyl-(1,3,5)-triazine-2,4-diamine is excluded.

Another special group of compounds are those compounds having the formula

CLV hi hd ~ Ty (1-2)

NAN SEN, the N-oxides, addition salts, quaternary amines and stereochemically isomeric forms thereof, wherein -b'=b>C(R%)=b’-b‘= represents a bivalent radical of formula -CH=CH-C(R®)=CH-CH= (b-1); -N=CH-C(R*=CB-CH= (b-2); -CH=N-C(R*)=CH-CH= (b-3);

-N=CH-C(R?*)=N-CH= (b-4); -N=CH-CR*)=CH-N= (b-5); -CH=N-CR*)=N-CH= ~~ (b-6);

N=N-CR*)=CH-CH= (b-7); qis 0, 1, 2; or where possible q is 3 or 4;

R! is hydrogen, aryl, formyl, C,.calkylcarbonyl, Ty.alkyl, C..salkyloxycarbonyl, C,.calkyl : substituted with formyl, C,calkylcarbonyl, C, salkyloxycarbonyl;

R* is cyano; aminocarbonyl; mono- or di(methyl)aminocarbonyl; C, alkyl substituted with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl; Cs.salkenyl substituted with cyano; or Ca.salkynyl substituted with cyano; cach R? independently is hydroxy, halo, C,.calkyl optionally substituted with cyano or -C(=0)R*, Cs.7cycloalkyl, C;.alkenyl optionally substituted with one or more halogen atoms or cyano, C; ¢alkynyl optionally substituted with one or more halogen atoms or cyano, C,salkyloxy, C,.calkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(Cj.salkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=0),R%, -NH-S(=0),R*, -C(=0)R*, -NHC(=O)H, _C(=0)NHNH,, -NHC(=O)R*,-C(=NH)R* or a radical of formula : “FA © : | Bf : : wherein each A independently is N, CH or CR*

Bis NH, O, S or NR; : . pis 1lor2;and

R® is methyl, amino, mono- or dimethylamino or polyhalomethyl;

L is Ca.joalkyl, Ca.10alkenyl, Ca j0alkynyl, Csscycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from * Cs.scycloalkyl, * indoly! or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, C)_galkyl, hydroxy,

C)-salkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, > polyhalomethyloxy and C).galkylcarbonyl, * phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R% or

L is -X-R? wherein

R® is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with two, three, four or five substituents each independently selected from the substituents defined in R% and

X is -NR'-, -NH-NH-, -N=N-, -O-, -C(=0)-, -CHOH-, -§-, -8(=0)- or -8(=0)~; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents eacn independently sclectad from hale, Cj galkyl, Csqcycloalkyl, Cy _galkyloxy, cyano, nitro, polyhaloC; galky! and pelyhaloC; salkyloxy: and suitably NN" -dipyridinyl-(1.3.5)-triazine-2,4-diamine is excluded.

Said special groups of compounds are deemed novel and can be used as a medicine.

The present invention also relates to a method of treating warm-blooded animals suffering from HIV (Human Immunodeficiency Virus) infection. Said method comprises the administration of a therapeutically effective amount of a compound of formula (I), (I’) or (I-a) or a N-oxide form, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof in admixture with a pharmaceutical carrier.

As used in the foregoing definitions and hereinafter Cysalkyl as a group or part of 2 group encompasses the straight and branched chain saturated hydrocarbon radicals having from 1 to 3 carbon atoms such as, methyi, ethyl and propyl; Ciualkyl : encompasses the straight and branched chain saturated hydrocarbon radicals as defined in C,alkyl as well as butyl; C, alkyl encompasses the straight and branched chain saturated hydrocarbon radicals as defined in Cyualky! as well as the higher homologues thereof containing 5 to 6 carbon atoms such as pentyl, hexyl, 2-methylbutyl and the like; C,.palkyl encompasses the straight and branched chain saturated hydrocarbon radicals as defined in C,calkyl as well as the higher homologues thereof containing 7 to 10 carbon atoms such as, heptyl, octyl, nony! or decyl; C,.oalkyl encompasses the straight and branched chain saturated hydrocarbon radicals as defined above, having from 4 to 10 carbon atoms; Cs.-cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; C, alkenyl defines straight and branched chain hydrocarbon radicals containing ene double bond and having from 2 to 6 carbon atoms such as, 2-ethenyl, 2-propenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, 3-hexenyl and the like; C,.0alkenyl encompasses the straight and branched chain > hydrocarbon radicals as defined in C.salkenyl as well as the higher homologues thereof containing 7 to 10 carbon atoms such as 3-heptenyl, 2-octenyl, 2-nonenyl, 2-decenyl and the like, whereby the carbon atom attached to the triazine ring is preferably an aliphatic carbon atom; C,calkynyl defines straight and branched chain hydrocarbon radicals containing one triple bond and having from 2 to 6 carbon atoms such as, 2-ethynyl, 2-propynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, 3-methyl-2-butynyi, 3-hexynyl and the like; C,.j0alkynyl encompasses the straight and branched chain hydrocarbon radicals as defined in C, alkynyl as well as the hi gher homologues thereof

} R td a: LJ -7- containing 7 to 10 carbon atoms such as 3-heptynyl, 2-octynyl, 2-nonynyl, 2-decynyl and the like, whereby the carbon atom attached to the triazine ring is preferably an aliphatic carbon atom. The term Cj.¢alkyloxy defines straight or branched chain saturated hydrocarbon radicals such as methoxy, ethoxy, propyloxy, butyloxy,

S pentyloxy, hexyloxy, 1-methylethyloxy, 2-methylpropyloxy, 2-methylbutyloxy and the like; Cs.ccycloalkyloxy is generic to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.

As used herein before, the term (=0) forms a carbonyl moiety when attached to a carbon atom, a sulfoxide group when attached once to a sulfur atom, and a sulfonyl group when attached twice to a sulfur atom.

The term halo is generic to fluoro, chloro, bromo and iodo. As used in the foregoing and hereinafter, polyhalomethy] as a group or part of a group is defined as mono- or polyhalosubstituted methyl, in particular methyl with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl; polyhaloC.alkyl as a group or part of a group is defined as mono- or polyhalosubstituted C;.¢alkyl, for example, the groups : defined in halomethyl, 1,1-difluoro-ethyl and the like. In case more than one halogen 1 atoms are attached to an alkyl group within the definition of polyhalomethyl or . 20 polyhaloC, alkyl, they may be the same or different. d For therapeutic use, salts of the compounds of formula (I), (I') or (I-a) are those wherein "the counterion is pharmaceutically acceptable. However, salts of acids and bases which : are not pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharma- ceutically acceptable or not are included within the ambit of the present invention.

The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I), (I') or (I-a) are able to form. The compounds of formula (I), (I) or (I-a) which have basic properties can be converted in their pharmaceutically > acceptable acid addition salts by treating said base form with an appropriate acid.

Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, : salicylic, p-aminosalicylic, pamoic and the like acids.

Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.

The compounds of formula (I), (I') or (I-a) containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

The term addition salts also comprises the hydrates and the solvent addition forms which the compounds of formula (I), (I') or (I-a) are able to form. Examples of such i” forms are e.g. hydrates, alcoholates and the like.

It will be appreciated that some of the compounds of formula (I), (I) or ({-a) and their

N-oxides, addition salts, quaternary amines and stereochemically isomeric forms may contain one or more centers of chirality and exist as stereochcmically isomeric forms.

The term “stereochemically isomeric forms” as used hereinbefore defines all the possible stereoisomeric forms which the compounds of formuta (@), (I) or (I-2) and their

N-oxides, addition salts, quaternary amines or physiologically functional derivatives may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixtuxe of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure : as well as each of the individual isomeric forms of formula (I), (I') or (I-a) and their

N-oxides, addition salts or quaternary amines substantially free, i.e. associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers. In particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration. Compounds encompassing double bonds can 5 have an E- or Z-siereochemistry at said double bond. Sterecchemically isomeric forms of the compounds of formula (I), (I') or (I-a) are sbviously intended to be embraced within the scope of this invention.

Some of the compounds of formula (I), (I') or (I-a) may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention. 40 Lines drawn into ring systems from substituents indicate that the bond may be attached

© to any of the suitable ring atoms.

When any variable (e.g. R?) occurs more than one time in any constituent, each s definition is independent.

Whenever used hereinafter, the term "compounds of formula (I)”, "compounds of formula (I)", or “compounds of formula (I-a)” is meant to include also the N-oxides, the addition salts, the quaternary amines and all stereoisomeric forms.

An interesting group of compounds are those compounds of formula (I) or I') wherein one or more of the following conditions are met : (i) nisl; (ii) -a'=a’-a’=a* represents a bivalent radical of formula (a-1); (iii) R' is hydrogen or alkyl; (iv) R% is cyano; aminocarbonyl; mono- or di(methyl)aminocarbonyl; C 1-salkyl : substituted with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl; and more in particular, R? is on the 4 position relative to the -NR'- moiety; i) Lis -X-R® wherein X is preferably -NR'-, -O- or -S-, most preferably X is -NH-, and R? is substituted phenyl with C,_salkyl, halogen and cyano as preferred substituents. 2 . Another interesting group of compounds contains those compounds of formula (1-2) i wherein one or more of the following restrictions apply : i) -b'=b-C(R¥)=b’-b*= is a radical of formula (b-1); ’ 25 ii) qisO; iii) R* is cyano; aminocarbonyl; mono- or di(methyl)aminocarbonyl; C,calkyl substituted with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl, preferably R* is cyano; iv) Lis -X-R? wherein X is preferably -NR'-, -O- or -S-, most preferably X is -NH-, and R® is substituted phenyl with C;_salkyl, halogen and cyano as preferred substituents. 5 : Preferred compounds are those compounds of formula (I') or (I-a) wherein Lis -X-R? wherein R? is a disubstituted phenyl group or a trisubstituted phenyl group, each substituent independently selected from chloro, bromo, fluoro, cyano or C;alkyl.

Compounds of formula (I') wherein L is a radical of formula -X-R?, said compounds are represented by formula (I-a), can be prepared by reacting an intermediate of : formula (IT) wherein W! is a suitable leaving group, for example, a halogen, with an 40 amine derivative of formula (II) in a reaction-inert solvent, for example, tetrahydro-

furan, 1,4-dioxane or the like, in the presence of a suitable base such as, triethylamine; and subsequently reacting the thus obtained intermediate of formula (IV) with an intermediate of formula (V) in 2 reaction-inert solvent such as acetonitrile, 1,4-dickane or the like, in the presence of a base such as potassium carbonate, sodium hydride,

NMN-diicopronvl-ethylamine or the like. w! R{ =x. R2), 1 4 \ i. = 3 yg (oF eu Fads 7 H als? \ (In (an 2! i av) \ ve dR Ja \ »”e

R*—X—H N= al—a? — Rx N v) - (ta)

The order of the above reaction scheme may also be reversed, i.e. first an intermediate of formula (I) may be reacted with an intermediate of formula (V), and then, the resulting intermediate may further be reacted with an amine derivative of formula (II); thus forming a compound of formula (I’-a).

The reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, extraction, crystallization, distillation, trituration and chromatography.

Compounds of formula (I') wherein L is an optionally substituted Ci-10alkyl,

Ca.10alkenyl, Ca.1alkynyl, Cascycloalkyl, said L being represented by L, and said compounds being represented by formula (I-b), can be prepared by first making a

Grignard reagent of an intermediate of formula (VI) wherein W? is a suitable leaving group such as, a halogen, e.g. bromine, in the presence of magnesium in a reaction-inert solvent such as, diethyl ether, and subsequently reacting said Grignard reagent with an 5 intermediate of formula (VII) wherein W' is a suitable leaving group such as, a halogen, e.g. chlorine, in a reaction-inert solvent, for example, benzene, thus forming an intermediate of formula (VII). It may be convenient to perform the above reaction under an inert atmosphere, for instance, argon. Intermediate (VIII) may be isolated from its reaction medium, or may be in situ further reacted with an intermediate of formula (I) in a reaction-inert solvent such as, 1,4-dioxane, and in the presence of a suitable base such as, diisopropylethylamine or the like, thus forming a compound of formula (I’-b).

. Z WO 00/27828 PCT/EP99/08688 -11- oo

R/ 3m RL = ®) k w! w! ed a Ww ys . —y a H ala’ n= al—2?

LeW4 Q wa —>| 5 Wa —_— I _/ (VD (Vin (VID Im I-b)

The compounds of formula (I') may further be prepared by converting compounds of formula (I’) into each other accordin g to art-known group transformation reactions.

The compounds of formula (I) may be converted to the corresponding N-oxide forms following art-known procedures for converting a trivalent nitrogen into its N-oxide form. Said N-oxidation reaction may generally be carried out by reacting the starting material of formula (I') with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboper- oxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarbo- peroxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. : 15 tbutyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated ’ hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

Some of the intermediates as mentioned hereinabove are commercially available or can be prepared according to art-known procedures.

Compounds of formula (I') and some of the intermediates may have one or more stereogenic centers in their structure, present in a R or a S configuration.

The compounds of formula (I') as prepared in the hereinabove described processes may be synthesized as a mixture of stereoisomeric forms, in particular in the form of racemic mixtures of enantiomers which can be separated from one another following > art-known resolution procedures. The racemic compounds of formula (I') may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I') involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods cf preparation. These methods will advantageously employ enantiomerically pure starting materials.

It will be appreciated by those skilled in the art that in the processes descri bed above the functional groups of intermediate compounds may need io be biucked Ly proteciig groups.

Functional groups which it is desirable to protect include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl groups (e.g. tert-butyldimethylsilyl, zert-butyldiphenylsiiyl or trimethylsilyl), benzyl and tetrahydro- pyranyl. Suitable protecting groups for amino include zert-butyloxycarbonyl or benzyl- oxycarbonyl. Suitable protecting groups for carboxylic acid include C;¢alkyl or benzyl esters.

The protection and deprotection of functional groups may take place befors or after a reaction step.

The use of protecting groups is fully described in ‘Protective Groups in Organic

Chemistry’, edited by J W F McOmie, Plenum Press ( 1973), and ‘Protective Groups in

Organic Synthesis’ 2™ edition, T W Greene & P G M Wutz, Wiley Interscience (1991).

The compounds of formula (I), I’) and (I-a) show antiretroviral properties, in particular : against Human Immunodeficiency Virus (HIV), which is the aetiological agent of

Acquired Immune Deficiency Syndrome (AIDS) in humans. The HIV virus preferentially infects human T-4 cells and destroys them or changes their normal function, particularly the coordination of the immune system. As a result, an infected patient has an everdecreasing number of T-4 cells, which moreover behave abnormally.

Hence, the immunological defense system is unable to combat infections and neoplasms and the HIV infected subject usually dies by opportunistic infections such as pneumonia, or by cancers. Other conditions associated with HIV infection include thrombocytopaenia, Kaposi's sarcoma and infection of the central nervous system i characterized by progressive demyelination, resulting in dementia and symptoms such as, progressive dysarthria, ataxia and disorientation. HIV infection further has also been associated with peripheral neuropathy, progressive generalized lymphadenopathy (PGL) and AIDS-related complex (ARC).

The present compounds also show activity against HIV-1 strains that have acquired resistance to art-known non-nucleoside reverse transcriptase inhibitors. They also have 40 little or no binding affinity to human o-1 acid glycoprotein.

NS] oY : bo kJ - WO 00/27828 PCT/EP99/08688 -13-

Due to their antiretroviral properties, particularly their anti-HIV properties, especially : their anti-HIV-1-activity, the compounds of formula (D, @) or (I-a), their N-oxides, addition salts and stereochemically isomeric forms, are useful in the treatment of individuals infected by HIV and for the prophylaxis of these infections. In general, the compounds of the present invention may be useful in the treatment of warm-blooded animals infected with viruses whose existence is mediated by, or depends upon, the : enzyme reverse transcriptase. Conditions which may be prevented or treated with the compounds of the present invention, especially conditions associated with HIV and other pathogenic retroviruses, include AIDS, AIDS-related complex (ARC), progressive generalized lymphadenopathy (PGL), as well as chronic CNS diseases caused by retroviruses, such as, for example HIV mediated dementia and multiple sclerosis.

The compounds of the present invention or any subgroup thereof may therefore be used as medicines against above-mentioned conditions. Said use as a medicine or method of treatment comprises the systemic administration to HIV-infected subjects of an amount effective to combat the conditions associated with HIV and other pathogenic : retroviruses, especially HIV-1.

The compounds of the present invention or any subgroup thereof may be formulated ) . ‘into various pharmaceutical forms for administration purposes. As appropriate : compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are : desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be R ‘ employed such as, for example, water, glycols, oils, alcohols and the like in the case of : oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets.

Because of their ease in administration, tablets and capsules represent the most advantageous oral unit dosage forms, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and slunoss solution. Injectable suspensions may alsc be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included arc solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suiwbie weriing agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, €.g., as a transdermal patch, as a spot-on, as an ointment.

Apart from their pharmacological properties, some of the compounds of formula (I) have interesting physicochemical properties. For instance, they have goed selubility.

To aid solubility of the less soluble compounds of formula (I), suitable ingredients, e.g. cyclodextrins, may be included in the compositicns. Appropriate cyclodextrins are o-,

B-, cyclodextrins or ethers and mixed ethers thereof wherein one or more of the hydroxy groups of the anhydroglucose units of the cyclodextrin are substituted with Cj_galkyl, particularly methyl, ethyl or isopropyl, e.g. randomly methylated B-CD; hydroxyCj.galkyl, particularly hydroxyethyl, hydroxy-propyl or hydroxybutyl; carboxyC.galkyl, particularly carboxymethyl or carboxy-ethyl; Cj.¢alkylcarbonyl, particularly acetyl. Especially noteworthy as complexants and/or solubilizers are B-CD, randomly methylated B-CD, 2,6-dimethyl-8-CD, 2-hydroxyethyl-g-CD, 2-hydroxyethyl- y-CD, 2-hydroxypropyl-y-CD and (2-carboxymethoxy)propyl-B-CD, and in particular 2-hydroxypropyl-g-CD (2-HP-8-CD). : The term mixed ether denotes cyclodextrin derivatives wherein at least two cyclodextrin hydroxy groups are ctherified with different groups such as, for exampie, hydroxy-propyl and hydroxyethyl.

The average molar substitution (M.S.) is used as a measure of the average number of moles of alkoxy units per mole of anhydroglucose. The average substitution degree (D.S.) refers to the average number of substituted hydroxyls per anhydroglucose unit.

The M.S. and D.S. value can be determined by various analytical techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS) and infrared spectroscopy (IR). Depending on the technique used, slightly different values may be obtained for one given cyclodextrin derivative. Preferably, as measured by mass spectrometry, the

* vi WO 00127828 PCT/EP99/08688

M.S. ranges from 0.125 to 10 and the D.S. ranges from 0.125 to 3.

Other suitable compositions for oral or rectal administration comprise particles obtainable by melt-extruding a mixture comprising a compound of formula (I) and an appropriate water-soluble polymer and subsequently milling said melt-extruded mixture. Said particles can then be formulated by conventional techniques into pharmaceutical dosage forms such as tablets and capsules.

Said particles consist of a solid dispersion comprising a compound of formula (I') and one or more pharmaceutically acceptable water-soluble polymers. The preferred technique for preparing solid dispersions is the melt-extrusion process comprising the following steps : a) mixing a compound of formula (I') and an appropriate water-soluble polymer, b) optionally blending additives with the thus obtained mixture, c) heating the thus obtained blend until one obtains a homogenous melt, d) forcing the thus obtained melt through one or more nozzles; and . e) cooling the melt till it solidifies.

The solid dispersion product is milled or ground to particles having a particle size of less than 600 um, preferably less than 400 um and most preferably less than 125 pm. ) The water-soluble polymers in the particles are polymers that have an apparent viscosity, when dissolved at 20°C in an aqueous solution at 2 % (w/v), of 1 to 5000 . mPa.s, more preferably of 1 to 700 mPa.s, and most preferred of 1 to 100 mPa.s. For example, suitable water-soluble polymers include alkylcelluloses, hydrox yalkyl- celluloses, hydroxyalkyl alkylcelluloses, carboxyalkylcelluloses, alkali metal salts of carboxyalkylcelluloses, carboxyalkylalkylcelluloses, carboxyalkylcellulose esters, starches, pectines, chitin derivates, polysaccharides, polyacrylic acids and the salts : thereof, polymethacrylic acids and the salts and esters thereof, methacrylate : copolymers, polyvinylalcohol, polyalkylene oxides and copolymers of ethylene oxide ; and propylene oxide. Preferred water-soluble polymers are Eudragit E® (Rohm GmbH,

Germany) and hydroxypropyl methylcelluloses.

Also one or more cyclodextrins can be used as water soluble polymer in the preparation of the above-mentioned particles as is disclosed in WO 97/18839. Said cyclodextrins include the pharmaceutically acceptable unsubstituted and substituted cyclodextrins known in the art, more particularly a, P or y cyclodextrins or the pharmaceutically acceptable derivatives thereof.

Substituted cyclodextrins which can be used include polyethers described in

U.S. Patent 3,459,731. Further substituted cyclodextrins are ethers wherein the hydrogen of one or mare cyclodextrin hydroxy groups is replaced bv C1_gaikyi, hydroxvC1-galkyl, carboxy-Cj1-galkyl or Cj _galkyloxycarbonylC_galkyl or mixed ethers thereof. In particular such substituted cyclodextrins are ethers wherein the hydrogen of one or more cyclodextrin hydroxy-groups is replaced by Ci.3alkyl, hydroxyCp.4aikyl or carboxyC-paikyl or more in pasiicula by siliyl, ety, hydroxyethyl, hydroxypropyl, hydroxybutyl, carboxy-methyl or carboxyethyl.

Of particular utility are the B-cyclodextrin ethers, e.g. dimethyl-B-cyclodextrin as described in Drugs of the Future, Vol. 9, No. 8, p. 577-578 by M. Nogradi (1984) and polyethers, e.g. hydroxypropyl B-cyclodextrin and hydroxyethyl B-cyclodextrin, being examples. Such an alkyl ether may be a methyl ether with a degree of substitution of about 0.125 to 3, e.g. about 0.3 to 2. Such a hydroxypropyl cyclodextrin may for example be formed from the reaction between B-cyclodextrin an propylene oxide and may have a MS value of about 0.125 to 10, e.g. about 0.3 to 3.

A more novel type of substituted cyclodextrins is sulfobutylcyclodextrines.

The ratio of compound of formula (I') over cyclodextrin may vary widely. For example ratios of 1/100 to 100/1 may be applied. Interesting ratios of compound of formula (T') over cyclodextrin range from about 1/10 to 10/1. More interesting ratios range from about 1/5 to 5/1.

It may further be convenient to formulate the compounds of formula (I') in the form of nanoparticles which have a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 1000 nm.

Useful surface modifiers are believed to include those which physically adhere to the surface of the compound of formula (I') but do not chemically bond to said compound.

Suitable surface modifiers can preferably be selected from known organic and inorganic ’ pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products and surfactants. Preferred surface modifiers include nonionic and anionic surfactants.

Yet another interesting way of formulating the compounds of formula (I) involves a pharmaceutical composition whereby the compounds of formula (I’) are incorporated in hydrophilic polymers and applying this mixture as a coat film over many small beads,

< pn 2 = . § a o = = . [}] o . © = xX «a a oo 8 FE 5 EE] g uy — 5 8 = z pe £ 3 225873 ¢ 2 ET 2% 3,58% 8 = = 2 iS) g 2 og 8 SEZ § 8 58 i oo B 0 & B £z,35%%58% g

E 2 mis .s53E8E TEE, fu EfE£2d2gps8 . = 2] 5] 0 © w= ‘= Bh R=] [9 & — Z 2 §3 83248 48 282892 S > ww 8 ¢ 3 § Lh

TS °8 £28 2525800 EE E9223 58° 35§88¢88 g Ez Zz 2 8 Es 2w3B2 Sg 2 Eads 3 2 § PRE 228% ww 5 £2 BE§E E893 Es £3TETIs £35358 £28 go ®y5 oESR 25 55 8 3 vo 8 gg ¢° E59 8% 28 £8 .

Ze PE 33% 22b38f sesivir Sicz3iil 0 B= = = = 0 wom r=} 3. 6 a 3 1 5 8 83% £85 8 BE 2 0.2 2 9 5 ¢ £ EB bs 5 8 & 9 © o § £85 £¥ §8 Bs'g Sg5288y 220838 EE 22g ws g 8 — 9 <4 8 § 51 > 8% 2 0 8 8B 2x = w3 EE EZET B §F «=X 5 8§ g 532 885 %TE 8 = L = 6 = @ £5 8 5 2 8

EE 5&5 &£¢2¢% ESBESEESE 22 83 2 CEL BE E34

Sf GE 28F fefoSEsy giriiey fIEEfffn2 = 58 E8f 58S2sgfil siiiidd Seas sg Biz

ZT 2 Fw oS de HERES gas FT Efo=8 093 82 5:5 3 £ 8 =

EE £5. 8:E8 EES 5888; BEwbisnE TF EE ag5 §E ug 8 @ = 5 8 8 og EC 5 © = sg HSC 65 = - 9 w Do ® 8 = 0 oo A eh XX 0 a So 0 2 5 o = oT = a @ i [=] by . = . o 5S £3 8392 3if3s:8% EPiE;s g S25; PFE 3

Tog wg S 8 aw ££ 0F g wS 5 BS BEx& gE gu 8c tg 2x23 : o wu 1] LD ow [3] ao P32 EB z E 8 dd «8B © 8 PP = « ©O © 8 E 3 3 8 5X 2827 8 ec EE 8 8g dug 243 2 3 £ 5 © =] 9 = £3 = § 4 2 = 6 43 82 8S 86 9g 8 € EB 5F ES ec 5 =} o = 2538 SH,88S42 FSS wER £25 3 §& = 8 5% 2 3 cas f EsSS% EE Teds gu EE §E EE a 2 gs 3 ~~ 88 3 ES eS & oc XP = 8 5 3 BE = . 2 o 9 ow [3 g 8 1} =] a gs 5 S =» ww 9 J = 8 23 °F g 883 sptageidbh 5355238 5s HE. $83 ¢ 58 S<& 8 2EG4§ e858 48% 88 82,88 oS Eg fET [=3-"} = © a. ES] = g E H's 2 8 5 a w 5 8 g SE =] [=] oT oo . ge oO Cc Qe a > =} = Q © wu 5 4 2 EE 835 2g 0 uw = 2S 9 Xo EE 0 uv E3588 ¢ = = [) by = 2 a = 3 3 _» a ° 8 5 2 a d oo 248 3 5w EE 8g 8 ES 8 wid d 495-8 8§ = 3 g 2 3 - 2 g £8 a 3 bo; — -~ a A =] an o >] a o w 98 © UO 4 2 = 3 55558 288£35 34% EBiwgsey £28583 25 3 2 9 & 8 5 © = 8 2 == Ee gos § = 5 23 £ e 2¥ 32 Sfsf §redfvig 233 BSE. uo Es ET eS g§ g o 28 £ESzF a oF 2828-528E8E 82° mw = oa £ §

S a £3 2EE t5gE8g5c TELE §2wgg gob 3 a] q A. 2 . El = 9 a o ie og BEB a 3 ou = c > C8 a B53 § ~~ B g W © o [TI by =» wp A 3g EE ga ® ad = avs 2 8 = SEs 38% £58883 28 2 £ £5 3 8§ Spd S TEp8SE8e ZEFESE LD FERS EES EEE = a LO 5 0 a 9 Ey = 2 3 S a 285 8

I Ba EY SE 51 o = Sa Oo © = gg Fr 8 P= — gE & s SE - gd gc 27 242% 28 cES TEC ET gi552 ESE = ° 5 SE EEE: 78882528 sE55 EF dE SE 2S czv fil [= 4 = 2 = 3 J Sw o gga. 8388 FE DT bh] 8 o EE nw 2 8 5 5 8 = 2 2 EE 28 ES 8 ¢ & 5 3 E g8 x5 3528 = £3 42 BEE: ScEEERCE BEiiiiiiogciizziniic = 5S Ed E88 £58855 EE 72} : o “

I= —~ ha Ie -

a on £0 £ u

I=} = = = = 208 E 8 — g Sq EI Zw 8 ER # r—7 - wm ] [= Sg yom 8 0, § 8B SH 8 ° - o

Be = « 8 9 s & 5 8 Howe og EE] = Q << 5 wk B [= dd « ao a af or EB 0 . o£ & © 3 EER EEE EES EERE E25 8 g 8 2 £ 3 &~ E 2c § CD 8 8 Low 8 7 8 49 5 ow 8 Ev] d w EB 2 85% 5g dsb nE cE HY & 5g =] S o

EL iTiEgoREIigig gs 5 2 HEPES ERE: = Bel — ¢y 0 49g 9 aQ ~~ o oc = > I I= 5 £ SE oF 8 g b=

SIE EERIE) : SSEEL 718

Lat - © 3 ANUS z= fy

Hn i ZEEE GES 6 OI onou a > EB REY 8H = YG a & 5 “ ®% § 8

E a Nog ogg] g oo 0 8 wT = gd R © SQ 5 28 5585 2

EB wo oH 2 E 2 x ug LYE 2 3 = - = a £9 8 5} 8 8 #4 EA a R = dz zg, © wp = 8 5 B . ES 5 a © = a x 2 S £ 3]

IERIE & 8 gogo Eg 8 5d - : 8 Q . a good 7g Eo AP 9 = ERIE SRO EE 3 & = g + 8 EB @ 2 wu 0° eS rsd 35088888 — 9 5 + TEES 4882 5 ~% 8 F S28 9 EgT SE on QO 5 - § <= 235 2

BecipiRfupeanianiiac, 8 = =33FE3008

E8We tT ggn dg ~ og 2 d oO = EEE. © 50

EEE EER fe deEnd a 5 = Eos a. SE 9: wg. 58858

BUI IHL RE INE o . Ev Eg E382

REIN HHI HE = g SAE g EFL E — - & > » 9 1c = a 3g 3 2

SEERIANANIR EINE) 8 2 Es EEERZE

BILLIE 5 258585253 Ek

ER Eg 5 20 gg gC a a= a8 nN .8 ed Ss 3 3a 228

TIRE ELS RRS FRR PRE K 4 g 5S 822837389

HALE ER EIT ELE = 5 ACHES I I 2 BE 18 E® 5 ’ Q = : - wo Be

Er E8338 58898 EEC EEE = lS j=) 8 31% = : = goog og ot Ihe na P =< =

EERE EERIE LEER HE AE E SESE EL

2 8 & a #5 5 3 EH od L aoe 3 = 8 Es < 3B I<) g QE £8 E Jd 5g 68 2 8 a5 39 8 4 85 £5 O = = 8g ~v& E e 5 5 FESR ES = grow oH 538, E 2 Ts e880 585 8 a @ wh = 48 20 gow 8 oa HES Ss 5 & By g ES 2g 32 B @ Q y «Tw BB 8 2 8

EERE SEER ERR SRE EL g 5 “5BEggtLd

LEI a ar] 1 A ET — on —- =

HEI IE LE 4 8 = 2 8 28 Eg §

Se *EHE ESSE To 8a 85E Ty ow op u o] o = gg 5 89 F

HELENE EEE RRL 55 2 a tr. 3 E gg bkEg gga: sBosh ifgpiez iii [CO] = 8 = 242528273 §gppligidato 2zi8%dizEks ¢ ® yg EF Fg dass

IIIs Ii ER LEI iE) ES = © Sx 2 og 880 4 = HiLERILHEBL HIER IRz8EzaE§ © Pi = I 2 B=] Eos Ea E eB 2B od +3 AS = ] ® g Ek oH aw 6538 3 Poe a ono a 2% oi = 5 RHINE IE 2 ow © Sie s3 8% x s BILLIE SER83S 55%

S SR I 2 5 ok SE <5 5 0 8 =a gw 2a § E EE TR I 2=o8g gg d g li Eiigeiiiiiecci ce REITER wm ~~ 6 8B 88 BEF S TR 5 = & A 2 2 4 ©

I HINILEEIIHHER il 2 oS E88 go ja 9 Fh) Q

Sl fiieiloEsctgat i BEG - mE x §EFR 33

INE NC IP EE CR = fo) 2 Q SEES 55 2 a 2 8 83 4d Eg 8 £ = 8 =» Es%558 9 4 b CEE mom JK a 4 3B 2 a

E o t 48 5 8 ~ £3 88 — 7a) ~~ E% 2 z & — wv a & « oy

Co ¢ WO 0027828 PCT/EP99/08688 over MgSO, filtered and the filtrate was evaporated to give 5.27 g of yellow powder : that was subjected to flash chromatography on silica gel (eluent: 100% CHCl; to 90:10

CH,Cl,/Et,0). The pure fractions were collected and the solvent was evaporated to give 3.87 g of off white solid that was recrystallized from CH;CN, filtered off and dried, yielding 3.57 g (64.8%) of 4-[(4-chloro-1,3,5-triazin-2-yl)amino]benzonitrile (Intermediate 1). )

B. Preparation of the-final compounds

Example B.1 a) Intermediate (1) (0.00160 mol) was partially dissolved by stirring in 1,4-dioxane (10 ml). Sequentially, 2,4,6-trimethylbenzenamine (0.00164 mol) and N,N-bis- (1-methylethyl)ethanamine (0.00164 mol) were added, and the resulting suspension was heated to reflux with stirring. The mixture cleared at 40-50°C. After 4.5 days at reflux, the reaction was cooled to RT, diluted with Et,0, and treated with cold 1 M NaOH.

EtOAc was added to dissolve all of the material between the 2 layers. The organic phase was separated and extracted with cold 1 M NaOH. The combined aqueous fractions were washed with EtOAc, adding solid NaOH to adjust the pH to >10. The combined organic phases were dried (MgSO), filtered and the solvent was evaporated in vacuo to give 0.60 g brown waxy solid. This fraction was purified by flash column chromatography over silica gel (eluent: 100% CH,Cl, to 80:20 CH,Cly/Et;0). The pure } fractions were collected and the solvent was evaporated to give 0.40 g of white waxy solid that was recrystallized from CH3CN. The precipitate was filtered off and dried, : yielding 0.24 g (45.4%) of 4-[[4-[(2,4,6-trimethylphenyl)amino}-1,3,5-triazin-2-yl]- amino benzonitrile (compound 1). b) Intermediate (1) (0.00203 mol) and 1,4-dioxane (15 ml) were added to a flask equipped with a condenser. The mixture was stirred vigorously, and 2,6-dibromo-4-(1- methylethyl)benzenamine (0.00205 mol) and N-ethyl-N-(1-methylethyl)-2-propanamine (0.00207 mol) were sequentially added. The reaction was heated to reflux for 5 days (TLC showed some progress). Refluxing was maintained for another day (TLC showed ] further slow progress). After 12 days total, the reaction was a darker brown with some dark precipitate. The reaction mixture was cooled to room temperature, diluted with

EtOAc, treated with cold 1 M NaOH (2 x) leaving some brown insoluble solid at the interface. The aqueous phase was pH adjusted to > 10 with solid NaOH and was backwashed with EtOAc (2 x). The organic phases were combined, dried over MgSO, filtered and concentrated in vacuo to obtain 0.99g brown residue. Purification from reverse phase prep HPLC and lyophilization yielded 0.020 g of 4-[[4-[[2,6-dibromo-4- (1-methylethyl)phenyl]amino}-1,3,5-triazin-2-ylJamino]benzonitrile (2.0%, beige fluffy solid)’ mp. 245-247°C (compound 8). Co

¢) Intermediate (1) (0.00203 mol) and 1,4-dioxane (15 ml) were added to a flask equipped with a condenser. The mixture was stirred vigorously, and 2,6-dimethyl-4- £1, 1-dimethylethylbenzenamine (0.60703 mai) and N-cthyi-N-{l-methylsthyi}2- propanamine (0.00207 mol) were sequentially added. The reaction was heated tz refiux iciperature for 5 days (TLC showed high conversion). Refluxing was maintained for another day (TLC showed no further progress). The reaction was cooled to room temperature, diluted with EtOAc, and treated with cold 1 M NaOH. The aqueous phase was pH adjusted to >10 with solid NaOH and backwashed with EtOAc. The organic phases were combined and dried over MgSO. Concentration afforded 0.90 g tan foam.

The residue was purified by flash column chromatography over silica gel (eluent:

CH,Cl, to 90:10 CH,Cl»:Et,0). The pure fractions were collected and the solvent was evaporated to give 0.36 g white solid. This fraction was recrystallized from CH;CN, filtered off and dried. Yielding: 0.28 g of 4-[[4-[[2,6-dimethyl-4-(1,1-dimethylethyl)- phenyl]jaminol-1,3,5-triazin-2-yl]amino]benzonitrile (37.0%, white crystalline solid) (compound 9).

Example B.2 a) NaH (0.0025 mol) and THF (5 mi) were added to a flask equipped with an addition funnel. A solution of 2,4,6-trimethylphenol (0.00206 mol) in THF (15 ml) was added dropwise with stirring over 15 minutes. The reaction mixture was stirred at room temperature for 45 minutes. Intermediate (1) (0.00203 mol) was added in one portion.

The reaction mixture was stirred for 4 days. The reaction was quenched by pouring over ice (75 ml). Upon melting, a minimal amount of precipitate formed. The mixture was treated with Et,O and EtOAc and the fractions were separated. The pH of the aqueous fraction was adjusted to >10 by treatment with solid NaOH and extracted with EtOAc.

The combined organic phases were treated with cold 1 M NaOH. The organic phases were dried over MgSO. Concentration in vacuo afforded 0.65 g white powder. This : fraction was recrystallized from CH3CN, filtered off and dried, yielding 0.50 g (74.4%) of 4-[[4-(2,4,6-trimethylphenoxy)-1,3,5-triazin-2-ylJamino] benzonitrile (compound 2). b) 1-Methyl-2-pyrrolidinone, (5 ml) was added to 3,5-dimethyl-4-hydroxybenzonitrile 7 (0.00258 mol) in a sealed tube reaction flask. The tube was capped with a septum and

Ar was introduced via a syringe needle. NaH 60% in oil (0.0030 mol) was added in one portion, and the reaction was stirred for 30 min as the mixture effervesced and became an orange solution. A suspension of intermediate (1) (0.00173 mol) in 1,4-dioxane (15 ml) was added and the flask was sealed and then heated to 160-170°C for 64 hours.

The reaction mixture was cooled to room temperature and analyzed by HPLC/MS which showed some desired product formation with complete consumption of intermediate (1). The sample was poured into ice (+200 ml) and allowed to melt. A

. y

Sl ~ ' WO 00/27828 PCT/EP99/08688 21- precipitate formed and the mixture was cooled in the refrigerator. Collected 0.31g brown powder by suction filtration which was subjected to purification through preparative HPLC. Upon lyophilization, obtained 0.02 g of 4-[[4-[(4-cyanophenyl)- amino}-1,3,5-triazin-2-ylJoxy]-3,5-dimethylbenzonitrile beige flaky solid (3.4%); mp. 248-250°C (compound 11).

Example B.3 )

Intermediate (1) (0.00203 mol) and 1,4-dioxane (15 ml) were added to a flask and stirred. Sequentially, 2,4,6-trimethylbenzenethiol (0.00204 mol) and N,N-bis(1-methyl- : ethyl)ethanamine (0.00207 mol) were added and stirred at ambient temperature. After stirring for one hour, THF (10 ml) was added. The reaction mixture was heated to reflux for 64 hours and cooled to RT. The reaction mixture was diluted with EtOAc and treated with cold 1 M NaOH. The aqueous phase was extracted with EtOAc while maintaining the pH >10 with the addition of solid NaOH. The combined organic phases were dried over MgSO, and concentrated to afford 0.75 g yellow powder. The residue ; 15 was crystallized from CH3CN, filtered off and dried, yielding 0.64 g (90.7%) of } 4-([4-1(2,4,6-trimethylphenyl)thio]-1,3,5-triazin-2-ylJamino]benzonitrile (compound 3).

Table 1 lists the compounds of formula (I’) which were prepared according to one of the above examples. - 20 Tablel

H

R? =

L X N

5

RE

Fr ll

No. ’ 1 Bla -NH- | CH; CH; CH; mp. 248-249°C 3 B2a -O- | CH; [Br Cl mp. 221-222°C . 4 B3 -S CH; | CH; CH; | mp. 256-257°C : 5 B2a -O- (Br CH; Br mp. 255-257°C : 6 Bla -NH- | Br CH; Br mp. 285-286°C : 7 Bla |-NH-|CH; |Br CH; | mp. 248-249°C 8 Blb -NH- | Br CH(CH3); |Br mp. 245-247°C 9 Bic -NH | CH; | C(CHj)s CH; | mp. 249-250°C 10 Blc -NH |CH; |CN CH; | mp. 252-254°C 11 B2b -O- |CHs [CN CH; | mp. 248-250°C

C. Pharmacological example

Example C.1

A rapid, sensitive and automated aseay procedure WAS used for the iz vitrg evaluation of anti-HIV agents. An HIV-1 transformed T4-cell line, MT-4, which was previously chown (Koyanagi et al Int. J. Cancer, 36, 445-451. 1985) to be highly susceptible to and permissive for HIV infection, served as the target cell line. Inhibition of the HIV- induced cytopathic effect was used as the end point. The viability of both HIV- and mock-infected cells was assessed spectrophotometrically via the in situ reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The 50% cytotoxic concentration (CCsq in pM) was defined as the concentration of compound that reduced the absorbance of the mock-infected control sample by 50%. The percent protection achieved by the compound in HIV-infected cells was calculated by the following formula : (OD1)mv - (CBomv

OPOmock - (OPOmY expressed in %, whereby (ODp)yv is the optical density measured with a given concentration of the test compound in HIV-infected cells; (OD) is the optical density measured for the control untreated HIV-infected cells; (ODc)mock is the optical density measured for the control untreated mock-infected cells; ali optical density values were determined at 540 nm. The dose achieving 50% protection according to the above formula was defined as the 50% inhibitory concentration (ICsq in uM). The ratio of CCsq to IC5q was defined as the selectivity index (SI). The compounds of formula (I’) were shown to inhibit HIV- 1 effectively. Particular IC50, CCs0 and SI values are listed in Table 3 hereinbelow.

Table 2

No. No. 1 | 0.0004 9.1 22722 5] 0.0016 10.1 6452 2| 00006 | >100 |>166666 | 6 | 0000s | 10 | 1901 | i 31 0.0011 56.2 53536 7 { 0.0007 27.8 39722 4 | 0.0022 >100 >46511

Claims (23)

i oA >) oo LT WO 00/27828 | EA oo PCT/EP99/08688 -23- Claims.

1. A compound of formula

R . | 2 . : L N Ne j;—a° (Ry : YY ke 5 0 N ZN al==2a? Low a N-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form - thereof, wherein — : -a'=a’-a’=a"- represents a bivalent radical of formula -CH=CH-CH=CH- (a-1); ) -N=CH-CH=CH- (a-2); -N=CH-N=CH- (a-3); -N=CH-CH=N- (2-4); -N=N-CH=CH- (a-5), nis 0, 1, 2, 3 or 4; and in case -a'=a%-a’=a%- is (a-1), then n may also be 5; R! is hydrogen, aryl, formyl, C, salkylcarbonyl, C, alkyl, C,.calkyloxycarbonyl, C, alkyl: substituted with formyl, C,salkylcarbonyl, C, salkyloxycarbonyl; and each R? independently is hydroxy, halo, Cj-galkyl optionally substituted with cyano or -C(=0)R*, C3.cycloalkyl, C;.salkenyl optionally substituted with one or more halogen atoms or cyano, C;.¢alkynyl optionally substituted with one or more halogen ' atoms or cyano, C, calkyloxy, C,salkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C,.¢alkyl)amino, polyhalomethyl, polyhalomethyloxy, ) 20 polyhalomethylthio, -S(=0),R?, -NH-S(=0),R*, -C(=O)R*, -NHC(=O)H, 5 -C(=0)NHNH,, -NHC(=O)R*,-C(=NH)R* or a radical of formula A ©) Bf wherein each A independently is N, CH or CRY Bis NH, O, S or NR*; pis 1 or 2; and ’ R* is methyl, amino, mono- or dimethylamino or polyhalomethyl; L is Ca.10alkyl, Cz.10alkenyl, Cs.joalkynyl, C3.scycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from } * Cs.cycloalkyl, * indolyl or isoindolyl, each optionally substituted with one, two, three or four “ substituents each independently selected from halo, C, alkyl, hydroxy, : C,alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C,.alkylcarbonyl,

b PCT/EP99/08688 * phenyl, pyridinyl, pyrimidiny}, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R? or L is -X-R® wherein R* is phenyl, pyridinyl, pyrimidinyl, pyraziny] or pyridazinyl, wherein each of said aromalic rings may optionally be substitufed with two, three, four or five substituents each independently selected from the substituents defined in RZ and X is -NR'-, -NH-NH-, -N=N-, -0-, -C(=0)-, -CHOH-, -S-, -5(=0)- or -8(=0),-; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C,ealkyl, Caqcycloalkyl, C,salkyloxy, cyano, nitro, polyhaloC, alkyl and polyhaloC,_salkyloxy; : with the proviso that compounds wherein * Lis C,,alkyl; R'is selected from hydrogen, ethyl and methyl, -a'=a’-a’=a‘- represents a bivalent radical of formula (a-1); nis 0 or 1 and R is selected from fluoro, chloro, methyl, trifluoromethyl, ethyloxy and nitro; or

__. *1i4s-X-R% Xs -NH-; R! is hydrogen; -a'=a’-a’=a’- represents a bivalent radical of So formula (a-1); mis 0 or 1 and R® is selected from chloro, methyl, methyloxy, cyano, "amino, and nitro and K is phenyl, optionally substituted with one substituent selected : from chloro, methyl, methyloxy, cyano, amino and nitro; ’ : 20 and the compounds : oo * N,N -dipyridinyl-(1,3,5)-triazine-2,4-diamine; oo oo * (4-chloro-phenyl)-(4-(1-(4-isobutyl-phenyl)-ethyl)-(1,3,5) triazin-2-yl)-amine * 4,4[1,3,5-triazin-2,4-diyl)bisamino bisbenzenccarboximidamide are not included. Ss

2. A compound of formula oo ¥ RY, | . L N No. _bl q UTX we : NN bi A a vr : a N-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form : "thereof, wherein -b'=bCRP)=b’ b= represents a bivalent radical of formula : -CH=CH-C(R*)=CH-CH= (b-1); a -N=CH-CR*™=CH-CH= -(b-2); : : -CH=N-C(R*)=CH-CH= (b-3); oo oo -N=CH-C(R*)=N-CH= (b-4);

© .N=CH-CR®=CH-N= (b-5); | : . RE oo -CH=N-C(R*)=N-CH= (b-6); AMENDED SHEET w PCT/EP99/08688 -24a- N=N-C(R®)=CH-CH= (7); gis 0, 1, 2; or where possible q is 3 or 4; R' is hydrogen, aryl, formyl, C.salkylcarbonyl, C, alkyl, C,.calkyloxycarbonyl, C,calkyl oo substituted with formyl, C,calkylcarbonyl, C,salkyloxycarbonyl; R* is cyano; aminocarbonyl; mono- or di(methyl)aminocarbonyl; C..alkyl substituted _ - with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl; Ci.¢alkenyl substituted with cyano; or Coealkynyl substituted with cyano; each R” independently is hydroxy, halo, C, alkyl optionally substituted with cyano or -C(=0)R*, Cs.qeycloalkyl, Cogalkenyl optional y substituted with one or more oo 10 halogen atoms or cyano, Ca.galkynyl optionally substituted with one or more halogen . atoms or cyano, C,salkyloxy, C,salkyloxycarbonyl, carboxyl, cyano, nitro, amino, oo AMENDED SHEET

‘MN PCT/EP99/08688 mono- or di(C).salkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=0),R*, -NH-S(=0),R*, -C(=0)R*, -NHC(=0)H, - -C(=0)NHNH,, -NHC(=O)R* -C(=NH)R* or a radical of formula : TT © . A "5 wherein each A independently is N, CH or CR: Bis NH, O, S or NR pislor2;and : Ris methyl, amino, mono-or dimethylamino or polyhalomethyl; : : 1 is Ca.r0alkyl, Cs.ipalkenyl, Ca.10alkynyl, Ci.scycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from * Cj.qcycloalkyl, * indolyl] or isoindolyl, each optionally substituted with one, two, three or four } : substituents each independently selected from halo, Cj.galkyl, hydroxy, :

Cj.salkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl,- <0 So 15 polyhalomethyloxy and C;_galkylcarbonyl, E Co * phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said oo aromatic rings may optionally be substituted with one, two, three, four or five IE ’ substituents each independently selected from the substituents defined in R?; or : Lis -X-R® wherein : : R® is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said : aromatic rings may optionally be substituted with two, three, four or five oo substituents each independently selected from the substituents defined in R? and - X is -NR'-, -NH-NH-, -N=N-, -O-, -C(=0)-, -CHOH-, -5-, -8(=0)- or -S(=0),-; ary! is phenyl or phenyl substituted with one, two, three, four or five substituents each : independently selected from halo, Cj.galkyt, Csncycloalkyl, Cy_galkyloxy, cyano, nitro, polyhaloC alkyl and polyhaloC salkyloxy; ~ with the proviso that the compound 2,4-di-p-cyanoanilino-1 ,3,5-triazine "is notincluded. Co 30

3. A compound as claimed in any one of claims 1 and 2 wherein L is -X-R%, -X- is -O- : © or-NH-andR’is phenyl substituted with two or three substituents each : : : : independently selected from chloro, bromo, cyano and methyl. : .

4. A compound as claimed in claim 2 wherein R* is cyano, aminocarbonyl, mono- or di(methyl)aminocarbonyl, C, alkyl substituted with cyano, aminocarbonyl or mono- EE or di(methyl)aminocarbonyl.

5. The use of a compound of formula AMENDED SHEET

R! mds NANTES cL Nr N Nd - a N-oxide, a pharmaceutically acceptable addition salt, a Guattinary amine or a stereochemically isomericform thereof, wherein

.a'=a®a’=a’- represents a bivalent radical of formula -CH=CH-CH=CH- {a-1); -N=CH-CH=CH- (a-2); -N=CH-N=CH- (a-3); -N=CH-CH=N- (a-4); -N=N-CH=CH- (a-5); nis 0, 1,2, 3 or 4; and in case -a'=a’-a’=a*- is (a-1), then n may also be 5; R'is hydrogen, aryl, formyl, C,zalkyicarbonyl, C, alkyl, C.salkyloxycarbony., Co salky. substituted with formyl, C, calkylcarbonyl, C,.salkyloxycarbonyl; and each R? independently is hydroxy, hale, C1_galky! optionally substituted with cyano or i5 -C(=0)R*, Cscycloalkyl, C;.salkenyl optionally substituted with one or more halogen atoms or cyano, Cy.¢alkynyl optionally substituted with one or more halogen atoms or cyano, C,salkyloxy, C, salkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C;.salkyl)amino, polyhalomethyl, polyhalomethyloxy, ] polyhalomethylthio, -S(=O);R*, -NH-S(=0),R*, -C(=0)R*, -NHC(=O)H, -C(=0)NHNH,, -NHC(=0)R*,-C(=NH)R* or a radical of formula he {c) A wherein each A independently is N, CH or CRY Bis NH, O, S or NR; pis 1or2; and R* is methyl, amino, mono- or dimethylamino or polyhalomethyl; L is Cy.1oalkyl, Ca. yoalkenyl, Ca.10alkynyl, Ciscycloalkyl, whereby each of said aliphatic ” group may be substituted with one or two substituents independently selected from * Csscycloalkyi, * indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, Cy.calkyl, hydroxy,

C..calkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C, calkylcarbonyl, * phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R* or Lis XR’ wherein R’ is phenyl, pyridinyl, pyrimidinyl, pyraziny! or pyridazinyl, wherein each of said = aromatic rings may optionally he suhstitnted with one, two, three, four or five substituents each independently selected from the substituents defined in R* and X is -NR'-, -NH-NH-, -N=N-, -O-, -C(=0)-, -CHOH-, -S-, -§(=0)- or -S(=0);-; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C,salkyl, C3cycloalkyl, C, calkyloxy, cyano, nitro, polyhaloC;.¢alkyl and polyhaloCi.ealkyloxy; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

6. A compound as claimed in any one of claims 1 tc 4 for use as a medicine.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of compound as claimed in any one of claims 1 10 4.

8. A process for preparing a pharmaceutical compostion as claimed in claim 7 characterized in that a therapeutically effective amount of a compound as claimed in . any onc of claims 1 to 4 is intimately mixed with a pharmaceutically acceptable carrier.

i 9. A process for preparing a compound as claimed in any one of claims 1 to 4, ora N-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof, characterized by a) reacting an intermediate of formula (II) with an amine derivative of formula (IIT) and subsequently reacting the thus obtained intermediate of formula (IV) with an inter- mediate of formula (V) in a reaction-inert solvent in the presence of a suitable base; w! Re { ® i wd + ve fn — wl ed \ \/ i \_4 \, J a (am av) R {3 N \ i) R*—X%—H —( ala? —_— wl pa v) ~~ a wherein W! is a suitable leaving group and R' to R>, X, n and -a'=a’-a’=a*- are as defined in claim 1; b) reacting an intermediate of formula (VI) with an intermediate of formula (VII) and 3 subsequently reacting the thus obtained intermediate of formula (VIII) with an amine derivative of formula (III) in a reaction-inert solvent in the presence of a suitable hase; - SC bY Ra RR /~%_® = m= H aa n= al—a? LW J — | = Wi | — = Wi (VD (VID (VID (0m @-b) wherein W! W? are suitable leaving groups, La is an optionally substituted C,.joalkyl, Csipalkenyt, Cooalkynyl, Cygcycloalky! and R! R? 1 and -a'=a?-2’=2"- are as defined inclaim 1; or if desired, converting compounds of formula (I') into each other following art-known transformations, and further, if desired, converting compounds of formula (I') into a i5 therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition sait into the free acid by treatment with acid; and, ) if desired, preparing stersochemically isomeric forms or N-oxides thereof. -

10. The combination of a compound as defined in any one of claims 1 t0 5 and another antiretroviral compound.

11. A combination as claimed in claim 10 for use as a medicine.

12. A product containing (a) a compound as defined in any one of claims 1 to 5, and (b) another antiretroviral compound, as a combined preparation for simultaneous, > separate or sequential use in anti-HIV treatment.

13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound as defined in any one of claims 1 to 5, and (b) another antiretroviral compound.

. gy PCT/EP99/08688

14. A substance or composition for use in a method for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection, said substance or composition comprising a compound as defined in claim 5, and said method comprising administering said substance or composition.

15. A compound as claimed in claim 1 or claim 2, substantially as herein described and illustrated.

16. Use as claimed in claim 5, substantially as herein described and illustrated.

17. A compound or a combination for use as a medicine as claimed in claim 6 or claim 11, substantially as herein described and illustrated. -

18. A composition as claimed in claim 7 or claim 13, substantially as herein described and illustrated. Y :

19. A process as claimed in claim 8 or claim 9, substantially as herein described ’ and illustrated.

20. A combination as claimed in claim 10, substantially as herein described and illustrated.

21. A product for use in treatment as claimed in claim 12, substantially as herein described and illustrated.

22. A substance or composition for use in a method of treatment as claimed in claim 14, substantially as herein described and illustrated.

23. A new compound, new use of a compound as defined in claim 5, a compound or combination for a new use as a medicine, a new composition, a new AMENDED SHEET hy } . w PCT/EP99/08688 process for preparing a composition or a compound, a new combination, or a substance or composition for a new use in a method of treatment, substantially as herein described.

AMENDED SHEET